化疗免疫治疗。
Chemoimmunotherapy.
机构信息
Department of Oncology, The Johns Hopkins University, 1650 Orleans St, Room 409, Bunting Blaustein Cancer Research Building, Baltimore, MD 21231-1000, USA.
出版信息
Cancer J. 2010 Jul-Aug;16(4):295-303. doi: 10.1097/PPO.0b013e3181eb5066.
Cancer chemotherapy drugs are historically regarded as detrimental to immunity because of their myelosuppressive effects. However, accumulating data suggest that the antitumor activity of conventional cancer chemotherapy results in part from its ability to harness the innate and adaptive immune systems by inducing immunologically active tumor cell death. Additional data broaden the immunologic effect of cancer chemotherapy drugs, demonstrating that some drugs have the ability to disrupt pathways of immune suppression and immune tolerance in a manner that depends on the drug dose, and the timing of its administration in relation to immunotherapy. Understanding the cellular and molecular basis of the interactions between chemotherapy drugs and the immune system will facilitate the strategic development of chemoimmunotherapy treatment regimens that both maximize tumor regression and the antitumor immune response for the long-term clinical benefit of cancer patients.
癌症化疗药物因其骨髓抑制作用而在历史上被认为对免疫有害。然而，越来越多的数据表明，传统癌症化疗的抗肿瘤活性部分源于其通过诱导具有免疫活性的肿瘤细胞死亡来利用先天和适应性免疫系统的能力。更多的数据扩展了癌症化疗药物的免疫效应，表明一些药物具有通过药物剂量和给药时间与免疫疗法的关系来破坏免疫抑制和免疫耐受途径的能力。了解化疗药物与免疫系统相互作用的细胞和分子基础将有助于制定化疗免疫治疗方案，这些方案既能最大限度地促进肿瘤消退，又能增强抗肿瘤免疫反应，从而为癌症患者带来长期的临床获益。
Zotero 插件